ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited. 

ACC 2022 - Estudio POISE-3: Ácido tranexámico en pacientes sometidos a cirugía no cardíaca

The aim of this study was to assess whether tranexamic acid reduces the incidence of bleeding events, which include life threatening bleeding, major bleeding, or bleeding into a critical organ (superiority design) and MACE incidence assessment (non-inferiority design) at 30 days, compared against placebo. 

The study randomized 9535 patients, mean age 69, considered at risk of bleeding and cardiovascular events, 76.8% with non-orthopedic surgery. The dose of tranexamic acid was 1gr. both at the start and end of surgery. 

The use of tranexamic acid significantly reduced bleeding incidence (HR 0.76, CI95% 0.67-0.87, p.001), with no evidence of MACE reduction (HR 1.02, CI95% 092-1.14, p: 0.04) and without reaching non-inferiority.

Read also: STEMI: Can We Omit Stenting?

Within the adverse events there was higher risk of seizures (HR 3.35), with no significant differences in serious events (5.5% vs 5.1% p:0.16).

Conclusions 

In patients at risk of bleeding and cardiovascular events set to receive non-cardiac surgery, the use of tranexamic acid significantly reduces bleeding compared against placebo. Despite the low rate of MACE in both groups, non-inferiority was not reached for cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board, SOLACI.org

Original Title: Poise-3: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Reference: Devereaux, P. J., Marcucci, M., Painter, T. W., Conen, D., Lomivorotov, V., Sessler, D. I., Chan, M. T. V., Borges, F. K., Martínez-Zapata, M. J., Wang, C.-Y., Xavier, D., Ofori, S. N., Wang, M. K., Efremov, S., Landoni, G., Kleinlugtenbelt, Y. V., Szczeklik, W., Schmartz, D., Garg, A. X., … POISE-3 Investigators. (2022). Tranexamic acid in patients undergoing noncardiac surgery. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2201171


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...